FDA approves generic versions of Johnson & Johnson’s Levaquin

The FDA on Monday approved the first generic versions of Johnson & Johnson’s Levaquin (levofloxacin). US regulators approved generic forms of the drug, both in tablet and injectable solution forms, manufactured by a dozen companies, including Mylan and Teva.

Other drugmakers that also received approval for a generic version of the antibiotic include Akorn, Aurobindo, Dr. Reddy’s, Glenmark Pharmaceuticals, Hi-Tech Drugs, Lupin, Sagent Pharmaceuticals, Torrent Pharmaceuticals and Wockhardt.

In its most recent quarterly results, Johnson & Johnson recorded $434 million in revenue from Levaquin and Floxin.

To read more Top Story articles, click here.